Skip to main content

Table 1 Availability of the asthma-COPD drugs and diagnostic tests in private and public hospitals and private pharmacies (n = 130)

From: Access to affordable medicines and diagnostic tests for asthma and COPD in sub Saharan Africa: the Ugandan perspective

   Availability (%)
A: Selected medicines (N = 10 classes and 2 types of spacers) Availability (%) in all study sites (N = 130) Public hospitals (N = 23) Private hospitals (N = 22) Private pharmacies (N = 85) P value
Inhaled LAMA monotherapies 0.0 0.0 0.0 0.0 NA
Inhaled LABA and LAMA combinations 0.0 0.0 0.0 0.0 NA
Inhaled LABA monotherapies 10.0 0.0 0.0 15.3 0.022
Inhaled SABA and SAMA combinations. 10.8 0.0 4.6 15.3 0.065
Inhaled SAMA monotherapy 12.3 0.0 0.0 18.8 0.008
Oral methylxanthines 16.9 4.0 18.2 20.0 0.203
Adult spacer devices 18.5 0.0 0.0 28.2 <0.001
Paediatric spacer devices 19.2 0.0 4.6 28.2 0.002
ICS monotherapies 45.4 4.0 50.0 55.3 <0.001
Inhaled LABA- ICS combinations 46.9 0.0 40.9 61.2 <0.001
Oral LTRA 60.8 0.0 59.1 76.7 <0.001
Inhaled SABA monotherapy 75.0 26.1 77.3 88.2 <0.001
B: Diagnostic/monitoring tests      
Peak flow-metry 6.7 8.7 4.6 NA 0.577
Spirometry 24.4 34.8 13.6 NA 0.099
  1. LAMA-Long acting anti muscarinic agents, LABA-Long acting beta agonists, SABA-Short acting beta agonists, SAMA-Short acting anti muscarinic agents, ICS-Inhaled corticosteroids, LTRA-Leukotriene receptor antagonists